{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T23:51:52Z","timestamp":1772063512844,"version":"3.50.1"},"reference-count":116,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1016\/s0268-960x(02)00057-7","type":"journal-article","created":{"date-parts":[[2002,12,28]],"date-time":"2002-12-28T07:34:16Z","timestamp":1041060856000},"page":"15-23","source":"Crossref","is-referenced-by-count":29,"title":["Molecular targets in acute myelogenous leukemia"],"prefix":"10.1016","volume":"17","author":[{"given":"Derek L","family":"Stirewalt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerald P","family":"Radich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0268-960X(02)00057-7_BIB1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/25870","article-title":"p19ARF links the tumour suppressor p53 to RAS","volume":"395","author":"Palmero","year":"1998","journal-title":"Nature"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/sj.onc.1203354","article-title":"Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines","volume":"19","author":"Hayakawa","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB3","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood.V96.12.3907","article-title":"Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways","volume":"96","author":"Mizuki","year":"2000","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/sj.onc.1203384","article-title":"H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism","volume":"19","author":"Delgado","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB5","doi-asserted-by":"crossref","DOI":"10.1016\/S1535-6108(02)00070-3","article-title":"CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)","author":"Kelly","year":"2002","journal-title":"Caner Cell"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0378-1119(02)00426-2","article-title":"The role of Rho GTPases in disease development","volume":"286","author":"Boettner","year":"2002","journal-title":"Gene"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1046\/j.1365-2141.1998.00554.x","article-title":"The molecular pathophysiology of myeloid leukaemias: Ras revisited","volume":"100","author":"Byrne","year":"1998","journal-title":"Br. J. Haematol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB8","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/366643a0","article-title":"Proteins regulating Ras and its relatives","volume":"366","author":"Boguski","year":"1993","journal-title":"Nature"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00062752-200207000-00003","article-title":"Role of FLT3 in leukemia","volume":"9","author":"Gilliland","year":"2002","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB10","first-page":"4682","article-title":"Ras oncogenes in human cancer: a review","volume":"49","author":"Bos","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB11","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1126\/science.1659742","article-title":"Growth factors and cancer","volume":"254","author":"Aaronson","year":"1991","journal-title":"Science"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0378-1119(94)90021-3","article-title":"Genomic structure of the downstream part of the human FLT3 gene: exon\/intron structure conservation among genes encoding receptor tyrosine kinases (RTK) of subclass III","volume":"145","author":"Agnes","year":"1994","journal-title":"Gene"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB13","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.V90.4.1345","article-title":"Stem cell factor and hematopoiesis","volume":"90","author":"Broudy","year":"1997","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB14","first-page":"1641","article-title":"Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR\/CSF1R family","volume":"6","author":"Rosnet","year":"1991","journal-title":"Oncogene"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB15","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1073\/pnas.91.2.459","article-title":"STK-1, the human homolog of Flk-2\/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor\/stem cells","volume":"91","author":"Small","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB16","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1126\/science.275.5307.1750","article-title":"Protein prenylation, et cetera: signal transduction in two dimensions","volume":"275","author":"Gelb","year":"1997","journal-title":"Science"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB17","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1042\/bst0240688","article-title":"Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics","volume":"24","author":"Koblan","year":"1996","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB18","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/jlb.65.3.372","article-title":"Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3\/Flt3 cells","volume":"65","author":"Zhang","year":"1999","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB19","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1038\/sj.onc.1202929","article-title":"Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor\/c-kit mediated activation of the Ras\/MAP kinase pathway and c-fos induction","volume":"18","author":"Lennartsson","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/emm.1999.13","article-title":"Role of Ras\/ERK-dependent pathway in the erythroid differentiation of K562 cells","volume":"31","author":"Kang","year":"1999","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB21","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0959-437X(97)80112-8","article-title":"Signal transduction from multiple Ras effectors","volume":"7","author":"Katz","year":"1997","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/385544a0","article-title":"Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB","volume":"385","author":"Kauffmann-Zeh","year":"1997","journal-title":"Nature"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB23","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1128\/MCB.16.7.3923","article-title":"Oncogenic Ras activation of Raf\/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation","volume":"16","author":"Khosravi-Far","year":"1996","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB24","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1038\/sj.onc.1201473","article-title":"Colocalization of Ras and Ral on the membrane is required for Ras-dependent Ral activation through Ral GDP dissociation stimulator","volume":"15","author":"Kishida","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB25","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1074\/jbc.272.3.1677","article-title":"p120 GAP modulates Ras activation of Jun kinases and transformation","volume":"272","author":"Clark","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB26","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1126\/science.8503013","article-title":"Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase","volume":"260","author":"Moodie","year":"1993","journal-title":"Science"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1126\/science.8385802","article-title":"A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf","volume":"260","author":"Lange-Carter","year":"1993","journal-title":"Science"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB28","doi-asserted-by":"crossref","first-page":"29773","DOI":"10.1074\/jbc.271.47.29773","article-title":"Regulation and interaction of pp90(rsk) isoforms with mitogen-activated protein kinases","volume":"271","author":"Zhao","year":"1996","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0898-6568(01)00185-1","article-title":"MEK, ERK, and p90RSK are present on mitotic tubulin in Swiss 3T3 cells: a role for the MAP kinase pathway in regulating mitotic exit","volume":"13","author":"Willard","year":"2001","journal-title":"Cell Signal"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB30","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1126\/science.7652575","article-title":"An essential role for Rho, Rac, and Cdc42 GTPases in cell cycle progression through G1","volume":"269","author":"Olson","year":"1995","journal-title":"Science"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0065-230X(08)60351-6","article-title":"Signaling by the cytokine receptor superfamily in normal and transformed hematopoietic cells","volume":"68","author":"Ihle","year":"1996","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB32","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1126\/science.7716517","article-title":"Cytokine signaling through nonreceptor protein tyrosine kinases","volume":"268","author":"Taniguchi","year":"1995","journal-title":"Science"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB33","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1038\/sj.onc.1205398","article-title":"JAKs, STATs and Src kinases in hematopoiesis","volume":"21","author":"Rane","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB34","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1073\/pnas.87.4.1377","article-title":"FMS mutations in myelodysplastic, leukemic, and normal subjects","volume":"87","author":"Ridge","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB35","first-page":"486","article-title":"Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia","volume":"4","author":"Tobal","year":"1990","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB36","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.leu.2401044","article-title":"RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up","volume":"12","author":"Padua","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB37","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1046\/j.1365-2141.1999.01449.x","article-title":"c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia","volume":"105","author":"Gari","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB38","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1046\/j.1365-2141.1998.01072.x","article-title":"Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val","volume":"103","author":"Sperr","year":"1998","journal-title":"Br. J. Haematol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB39","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB40","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/sj.leu.2401130","article-title":"Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product","volume":"12","author":"Kiyoi","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB41","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/sj.leu.2400756","article-title":"Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho)","volume":"11","author":"Kiyoi","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2141.1999.01284.x","article-title":"Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children","volume":"105","author":"Xu","year":"1999","journal-title":"Br. J. Haematol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB43","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/sj.leu.2400812","article-title":"Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines","volume":"11","author":"Yokota","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB44","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V97.11.3589","article-title":"FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia","volume":"97","author":"Stirewalt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.V97.1.89","article-title":"Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia","volume":"97","author":"Meshinchi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB46","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.leu.2401241","article-title":"Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children\u2019s Cancer and Leukemia Study Group, Japan","volume":"13","author":"Iwai","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB47","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V100.1.59","article-title":"Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease","volume":"100","author":"Schnittger","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB48","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1182\/blood.V99.12.4326","article-title":"Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis","volume":"99","author":"Thiede","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB49","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1046\/j.1365-2141.2000.02317.x","article-title":"FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group","volume":"111","author":"Abu-Duhier","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0925-5710(95)00389-A","article-title":"Biology of flt3 ligand and receptor","volume":"62","author":"Lyman","year":"1995","journal-title":"Int. J. Hematol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB51","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1182\/blood.V88.10.3987.bloodjournal88103987","article-title":"Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax","volume":"88","author":"Lisovsky","year":"1996","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB52","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB53","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1046\/j.1365-2141.2001.02850.x","article-title":"Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia","volume":"113","author":"Abu-Duhier","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB54","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood.V99.1.310","article-title":"FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model","volume":"99","author":"Kelly","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB55","doi-asserted-by":"crossref","first-page":"8283","DOI":"10.1073\/pnas.122233699","article-title":"PML\/RAR\u03b1 and FLT3-ITD induce an APL-like disease in a mouse model","volume":"99","author":"Kelly","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB56","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1073\/pnas.85.5.1629","article-title":"Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes","volume":"85","author":"Farr","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB57","first-page":"247","article-title":"Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci","volume":"3","author":"Bartram","year":"1989","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB58","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood.V76.4.801.801","article-title":"N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance","volume":"76","author":"Radich","year":"1990","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB59","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V69.4.1237.1237","article-title":"Mutations in N-ras predominate in acute myeloid leukemia","volume":"69","author":"Bos","year":"1987","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB60","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/gcc.2870020212","article-title":"RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study","volume":"2","author":"Vogelstein","year":"1990","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB61","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood.V83.6.1603.bloodjournal8361603","article-title":"Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia","volume":"83","author":"Neubauer","year":"1994","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB62","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.V82.2.590.590","article-title":"N-ras mutations are associated with poor prognosis and increased risk of leukemia in Myelodysplasia Syndrome","volume":"82","author":"Paquette","year":"1993","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB63","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood.V83.8.2248.2248","article-title":"Mutations of the N-ras gene in juvenile chronic myelogenous leukemia","volume":"83","author":"Miyauchi","year":"1994","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB64","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.leu.2401240","article-title":"RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)","volume":"13","author":"Flotho","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB65","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.V76.6.1214.1214","article-title":"RAS mutations are rare events in Philadelphia chromosome-negative\/bcr gene rearrangement-negative chronic myelogenous leukemia, but are prevalent in chronic myelomonocytic leukemia","volume":"76","author":"Hirsch-Ginsberg","year":"1990","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB66","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1182\/blood.V73.4.1028.1028","article-title":"Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia","volume":"73","author":"Collins","year":"1989","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB67","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/sj.leu.2400617","article-title":"Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells","volume":"11","author":"Towatari","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB68","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/sj.leu.2401369","article-title":"Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation","volume":"13","author":"Lida","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB69","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1182\/blood.V97.6.1823","article-title":"Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1\/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling","volume":"97","author":"Morgan","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB70","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(00)81902-9","article-title":"Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a","volume":"88","author":"Serrano","year":"1997","journal-title":"Cell"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB71","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1038\/sj.leu.2402317","article-title":"Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts","volume":"15","author":"Birkenkamp","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB72","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood.V95.12.3765","article-title":"Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6","volume":"95","author":"Schuringa","year":"2000","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB73","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1182\/blood.V97.11.3559","article-title":"Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells","volume":"97","author":"Ning","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB74","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1182\/blood.V90.7.2535","article-title":"Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia","volume":"90","author":"Peeters","year":"1997","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB75","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.278.5341.1309","article-title":"A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia","volume":"278","author":"Lacronique","year":"1997","journal-title":"Science"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB76","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","article-title":"BCR\u2013ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein","volume":"75","author":"Pendergast","year":"1993","journal-title":"Cell"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB77","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB78","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2141.2000.01831.x","article-title":"Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells","volume":"108","author":"Fenski","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB79","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia","volume":"105","author":"Druker","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB80","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1182\/blood.V90.12.4947","article-title":"CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR\u2013ABL, TEL\u2013ABL, and TEL\u2013PDGFR fusion proteins","volume":"90","author":"Carroll","year":"1997","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB81","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR\u2013ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB82","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.V96.3.925","article-title":"Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor","volume":"96","author":"Heinrich","year":"2000","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB83","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1006\/bcmd.1998.0191","article-title":"In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation","volume":"24","author":"Beghini","year":"1998","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB84","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB85","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V97.5.1413","article-title":"The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts","volume":"97","author":"Smolich","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB86","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood.V98.1.241","article-title":"Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia","volume":"98","author":"Mesters","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB87","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.20.6.1657","article-title":"Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors","volume":"20","author":"Kuenen","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB88","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/1074-7613(95)90167-1","article-title":"Targeted disruption of the flk2\/flt3 gene leads to deficiencies in primitive hematopoietic progenitors","volume":"3","author":"Mackarehtschian","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB89","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/sj.leu.2401680","article-title":"In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor","volume":"14","author":"Zhao","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB90","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.leu.2402199","article-title":"Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor","volume":"15","author":"Tse","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB91","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood.V98.3.885","article-title":"A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations","volume":"98","author":"Levis","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB92","first-page":"118a","article-title":"FLT3-targeted tyrosine kinase inhibitors inhibit proliferation, induce apoptosis, and improve survival in a murine leukemia model utilizing FLT3\/ITD-transformed cells","volume":"89","author":"Allebach","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB93","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood.V99.11.3885","article-title":"A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo","volume":"99","author":"Levis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB94","first-page":"721a","article-title":"FLT3-targeted inhibitors kill FLT3-dependent modeled cells, leukemia-derived cell lines, and primary AML blasts in vitro and in vivo","volume":"89","author":"Levis","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB95","article-title":"SU5416 and SU5614 inhibit wild-type and activated mutant FLT3 signaling in leukemia cells","volume":"89","author":"Yee","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB96","first-page":"118a","article-title":"Sugen compounds SU5416 and SU11248 inhibit Flt3 activity: therapeutic application in AML","volume":"89","author":"O\u2019Farrell","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB97","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S1535-6108(02)00069-7","article-title":"Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412","volume":"1","author":"Weisberg","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB98","doi-asserted-by":"crossref","first-page":"26802","DOI":"10.1074\/jbc.270.45.26802","article-title":"Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras\u2013Raf complexes","volume":"270","author":"Lerner","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB99","doi-asserted-by":"crossref","first-page":"19203","DOI":"10.1016\/S0021-9258(17)32153-1","article-title":"The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation","volume":"269","author":"Cox","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB100","first-page":"1846","article-title":"GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells","volume":"57","author":"Miquel","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB101","doi-asserted-by":"crossref","first-page":"20243","DOI":"10.1074\/jbc.273.32.20243","article-title":"A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells","volume":"273","author":"Sepp-Lorenzino","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB102","first-page":"4243","article-title":"Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion","volume":"55","author":"Sun","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB103","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.onc.1201656","article-title":"Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts","volume":"16","author":"Sun","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB104","first-page":"5302","article-title":"A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines","volume":"55","author":"Sepp-Lorenzino","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB105","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1128\/MCB.14.6.4193","article-title":"Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton","volume":"14","author":"Prendergast","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB106","first-page":"C19","article-title":"Farnesyltransferase inhibitors: targeting the molecular basis of cancer","volume":"1423","author":"Oliff","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB107","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/sj.onc.1202175","article-title":"Non-Ras targets of farnesyltransferase inhibitors: focus on Rho","volume":"17","author":"Lebowitz","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB108","doi-asserted-by":"crossref","first-page":"6105","DOI":"10.1128\/MCB.20.16.6105-6113.2000","article-title":"RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors","volume":"20","author":"Liu","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB109","first-page":"1871","article-title":"A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity","volume":"60","author":"Adjei","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB110","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1182\/blood.V100.3.1068","article-title":"Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336","volume":"100","author":"Hoover","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB111","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood.V97.5.1404","article-title":"Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR\/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia","volume":"97","author":"Peters","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB112","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1200\/JCO.2002.09.116","article-title":"Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer","volume":"20","author":"Crul","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB113","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","article-title":"Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial","volume":"97","author":"Karp","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0268-960X(02)00057-7_BIB114","first-page":"2104","article-title":"U0126 reverses Ki-ras-mediated transformation by blocking both mitogen-activated protein kinase and p70 S6 kinase pathways","volume":"60","author":"Fukazawa","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB115","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/BF03403538","article-title":"STAT signaling in the pathogenesis and treatment of cancer","volume":"5","author":"Frank","year":"1999","journal-title":"Mol. Med."},{"key":"10.1016\/S0268-960X(02)00057-7_BIB116","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1172\/JCI118905","article-title":"Interferon-\u03b3-mediated activation of STAT1\u03b1 regulates growth factor-induced mitogenesis","volume":"98","author":"Marra","year":"1996","journal-title":"J. Clin. Invest."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X02000577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X02000577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T16:28:48Z","timestamp":1622651328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X02000577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":116,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["S0268960X02000577"],"URL":"https:\/\/doi.org\/10.1016\/s0268-960x(02)00057-7","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}